Premium
Capecitabine and weekly paclitaxel as first‐line therapy in Thai patients with metastatic breast cancer
Author(s) -
CHITAPANARUX Imjai,
KAMNERDSUPAPHON Pimkhuan,
THARAVICHITKUL Ekasit,
LORVIDHAYA Vicharn,
TRAKULTIVAKORN Hongsin,
SRISUKHO Songpol,
SOMWANGPRASERT Areewan,
WATCHARACHAN Kirati,
SUKTHOMYA Vimol
Publication year - 2012
Publication title -
asia‐pacific journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.73
H-Index - 29
eISSN - 1743-7563
pISSN - 1743-7555
DOI - 10.1111/j.1743-7563.2011.01467.x
Subject(s) - capecitabine , medicine , tolerability , metastatic breast cancer , neutropenia , regimen , taxane , paclitaxel , gastroenterology , breast cancer , progressive disease , toxicity , oncology , cancer , surgery , chemotherapy , adverse effect , colorectal cancer
Aim: The combination of a taxane and capecitabine offers synergistic antitumor activity. This study aimed to determine the efficacy and tolerability of a paclitaxel and capecitabine combination in Thai patients with metastatic breast cancer (MBC) not previously treated for metastatic disease. Methods: This open‐label, single‐center, non‐comparative phase II study was conducted between December 2006 and March 2009. In all 40 MBC patients were treated with oral capecitabine 1000 mg/m 2 twice daily on days 1 to 14, and weekly paclitaxel 80 mg/m 2 in a 3‐week cycle for a total of six cycles. Results: After a median follow up of 13.4 months, an overall objective response rate of 80%, with a partial response of 74% and a complete response of 5% were achieved. While 8% of patients achieved stable disease, 13% had progressive disease. Median time to progress was 8 months and median overall survival was 24.4 months. One patient discontinued because of hypersensitivity to paclitaxel. There was no grade 4 toxicity. Skin and nail toxicity was found in 75% of patients (with 25% in grade 2 or 3), followed by neutropenia (45% in all with 15% in grades 2 or 3), neuropathy (25% in total with 5% in grade 2) and stomatitis and diarrhea (in both of which 5% experienced grade 1 severity). Conclusion: A first‐line regimen of weekly paclitaxel plus capecitabine is effective and tolerable in Thai MBC patients.